Evaxion Biotech A/S (EVAX)
NASDAQ: EVAX · IEX Real-Time Price · USD
3.720
-0.130 (-3.38%)
May 17, 2024, 3:59 PM EDT - Market closed
Company Description
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies.
The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy that is in pre-clinical stage for the treatment of various cancers.
Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases.
Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.
Evaxion Biotech A/S
| Country | Denmark |
| Founded | 2008 |
| IPO Date | Feb 5, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 49 |
| CEO | Christian Kanstrup M.Sc. |
Contact Details
Address: Dr Neergaards Vej 5f Hoersholm, G7 2970 Denmark | |
| Phone | 004531262615 |
| Website | evaxion-biotech.com |
Stock Details
| Ticker Symbol | EVAX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $10.00 |
| CIK Code | 0001828253 |
| CUSIP Number | 29970R105 |
| ISIN Number | US29970R2040 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Christian Kanstrup M.Sc. | Chief Executive Officer |
| Andreas Holm Mattsson | Co-Founder and Chief AI and Culture Officer |
| Jesper Nyegaard Nissen M.Sc. | Interim Chief Financial Officer and Chief Operating Officer |
| Dr. Niels Iversen Moeller M.D. | Co-Founder, Vice President of Business and Director |
| Dr. Birgitte Rono Ph.D. | Chief Scientific Officer |
| Dr. Jürgen Langhärig EMBA, Ph.D. | Head of Business Development and Member of Advisory Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 10, 2024 | 6-K | Report of foreign issuer |
| May 6, 2024 | F-1 | Registration statement for certain foreign private issuers |
| Apr 25, 2024 | 6-K | Report of foreign issuer |
| Apr 17, 2024 | 6-K | Report of foreign issuer |
| Apr 2, 2024 | 6-K | Report of foreign issuer |
| Mar 29, 2024 | 6-K | Report of foreign issuer |
| Mar 27, 2024 | 6-K | Report of foreign issuer |
| Mar 26, 2024 | 20-F | Annual and transition report of foreign private issuers |
| Mar 19, 2024 | 6-K | Report of foreign issuer |
| Mar 13, 2024 | 6-K | Report of foreign issuer |